NCT06626971 — The Use of ARA290 for the Treatment of Diabetic Macular Oedema
ClinicalTrials.gov registry summary, not a standalone efficacy publication.
NCT06626971: TERMINATED; 9 participants (actual). The registry reports termination because the study drug expired and no replacement was available, not because toxicity was established. The nine-participant macular edema publication reports null mean ocular endpoints and separate exploratory signals. No tabular results are posted in this registry record.
Registered clinical trial
Official ClinicalTrials.gov record.
- •Registry identifier: NCT06626971
- •Status: TERMINATED
- •Phase: PHASE2
- •Conditions: Diabetic Macular Oedema
- •Enrollment: 9 (ACTUAL)
- •Allocation: NA
- •Results posted: No
- •Registry last updated: 2024-10-04
- •Record checked: October 15, 2026
Interpretation and limitations
The registry reports termination because the study drug expired and no replacement was available, not because toxicity was established. The nine-participant macular edema publication reports null mean ocular endpoints and separate exploratory signals. No tabular results are posted in this registry record.
Registry reason for stopping: Expiry of study drug - no replacement available.
Read the related publication summary.
Registration records describe trial plans and administrative status. Completion alone does not establish efficacy; missing results do not prove treatment failure. The Educational evidence badge distinguishes these records from peer-reviewed human outcome studies. This is a dated registry snapshot, not live monitoring.
Connected compound
ARA-290 / cibinetide monograph. Research education only, not treatment advice.
Keywords
For research use only. Not medical advice.